Introduction
Introduction

Transforming growth factor ␤ (TGF␤) belongs to a superfamily of polypeptides that governs a number of cellular processes, including cell proliferation, differentiation, immunosuppression and synthesis of extra-cellular matrix proteins. TGF␤ exerts its action by binding to specific cell surface receptors. Three major types of receptors, named receptor type I, II and III, have been identified. The type II TGF␤ receptor (T␤RII) is a constitutively active cell surface serine/threonine kinase receptor
. T␤RII has affinity for TGF-␤1 and TGF-␤3 isoforms, but requires the accessory type III TGF␤ receptor (T␤RIII, betaglycan) to bind TGF-␤2 [2, 3] [4, 5] . In turn, transcription factors Smad2 and Smad3 are phosphorylated by T␤RI [6] 
. Upon ligand binding, T␤RII forms a complex with the type I TGF␤ receptor (T␤RI) and phosphorylates the juxtamembrane GS domain of T␤RI to activate its serine/threonine kinase
Material and methods
Cell culture and treatments
Human articular chondrocytes (HACs) were prepared from femoral head as previously described [9] . Cells were seeded at 4 
Gene-silencing experiments
RNA interference targeting p65 was performed as previously described using the plasmid shRNAp65 (short hairpin RNA p65) [9] . 
Nuclear extracts and EMSA
Nuclear extracts were prepared as previously described [10] . For (Fig. 3A) .
Chromatin immunoprecipitation assay
Moreover 
Fig. 2 IL-1␤ represses T␤RII expression via Sp1 site at position -25. A: HAC, transfected with an Sp1 consensus sequence (Sp1 decoy), were incubated in DMEM + 2% FCS in the presence or not of IL-1␤ (1 ng/ml) for 24 hrs. Thereafter, T␤RII mRNA versus GAPDH level was determined by RT-PCR. B: Subconfluent cultures of chondrocytes were treated with IL-1␤ (1 ng/ml) for 48 hrs in the presence or absence of mithramycin (100 or 150 nM). T␤RII expression was analysed at mRNA level by real-time RT-PCR (B).
Fig. 3 IL-1␤ enhances Sp1/Sp3 binding to T␤RII promoter (position -25). A: Electrophoretic mobility shift assay (EMSA) reactions were performed using the 5' end-labelled -47/-15 probe, incubated with 6 µg of nuclear extract from chondrocytes treated in the absence or in the presence of IL-
p65 (from nuclear extracts) followed by Western blot with Sp1 or Sp3 antibodies, showed that both factors were able to interact with p65 in the nucleus (Fig. 3B) and that IL-1␤ seemed to decrease these interactions. Similar results were obtained when Sp3 (or Sp1) were immunoprecipitated before immunoblotting with p65 antibody (data not shown). This suggests that NFB may indirectly bind to T␤RII core promoter via a physical interaction with Sp1 or Sp3.
To determine whether Sp1, Sp3 and p65 were recruited to the endogenous T␤RII promoter in vivo, ChIP was performed and followed by real-time PCR. As illustrated in Fig. 3C (Fig. 4B) . Moreover, to define whether Sp3 could be the de novo protein required for IL-1␤ effect on T␤RII [9] , we reproduced the experiment in the presence of cycloheximide. Our result (Fig. 4C) showed that the stimulation Fig. 4 IL-1␤ (Fig. 5A) . Sp3 siRNA) (Fig. 5B) . Fig. 6A . (Fig. 6B) 
Moreover, Sp3 over-expression mimes IL-1␤ effects
Silencing of Sp1 or Sp3, proven by both Western blot and RT-PCR, led to inhibition of T␤RII expression (Sp1 siRNA) or abolition of IL-1␤-induced repression of T␤RII (
In addition, transfections of wild-type or mutated T␤RII promoter constructs demonstrated that Sp3 represses T␤RII promoter activity via -47/-15 region as shown in
Taken together, these data suggest that IL-1␤ reduces T␤RII transcription through the induction of Sp3 expression and its binding on Sp1 site at -25 in T␤RII core promoter. To investigate whether Sp3 acts as a direct inhibitor of T␤RII transcription and/or as a repressor of an activator (Sp1), we investigated T␤RII mRNA expression after the silencing of both Sp1 and Sp3
NFB/p65 mediates IL-1␤ effect on T␤RII transcription via core promoter and by inducing Sp3 expression
We previously demonstrated that IL-1␤ down-regulates T␤RII through NFB/p65 pathway. However, EMSA experiments (Fig. 3) showed that this transcriptional factor weakly bind to the sequence of T␤RII promoter which mediates IL-1␤ effect. We attempted to understand its mechanism of action. Transient cotransfection of luciferase-driven T␤RII promoter constructs with p65 expression vector indicated that p65 decreases T␤RII transcription through the same region (-47/-15 bp) of the human promoter that Sp3 did at the -25 Sp1 site (Fig. 7) . This result confirms that p65 is a mediator of IL-1␤ effect on T␤RII expression. Furthermore, given that p65 is not able to strongly bind to the core promoter of T␤RII, we suggest that this factor could act indirectly through the modulation of Sp3 level. This hypothesis was confirmed since ectopic p65 over-expression led to a great induction of Sp3 expression (Fig. 8A) . In contrast, silencing of p65 by siRNA induced Sp3 mRNA decrease (Fig. 8B) . In the same way, blockade of NFB by PDTC or decoy oligonucleotide prevents induction of Sp3 by IL-1␤ (Fig. 8C and D) . Finally, using ChIP assay, we showed that p65 is able to bind in vivo to Sp3 promoter (Fig. 8E) [15] . Sp1 is necessary for the transcription of TATA-less genes, such as TGF␤ receptors genes, through its interaction with the TFIID to direct the start site of transcription [16] . Of interest is the fact that the promoters of other TGF␤ family members contain Sp1 sites. TGF␤1 and T␤RI genes have been shown to contain functionally significant Sp1 motifs in their promoters [17, 18] .
In 
